Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 425,107	$ 155,366	$ 864,099	$ 169,030
Amortization of license agreements remainder of fiscal year 2016	850,214		850,214
Amortization of license agreements in 2017	1,700,429		1,700,429
Amortization of license agreements in 2018	1,700,429		1,700,429
Amortization of license agreements in 2019	1,700,429		1,700,429
Amortization of license agreements in 2020	1,700,429		1,700,429
Amortization of license agreements in 2021	1,700,429		1,700,429
Amortization of license agreements, thereafter	13,662,723		$ 13,662,723
Novartis | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			21 years
Finite-lived intangible assets, accumulated amortization	160,772		$ 160,772
Novartis | Patents
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			14 years
Finite-lived intangible assets, accumulated amortization	1,681,359		$ 1,681,359
Roche RNAi | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			4 years
Finite-lived intangible assets, accumulated amortization	$ 230,000		$ 230,000